Infectious Diseases
Page 1 • 6 itemsGlobal pharma infectious disease market intelligence: track R&D, regulatory approvals, and investment trends for novel antivirals, antibacterials, and vaccines.
Acurx DNA pol IIIC Inhibitors Show Gut Microbiome Preservation in MRSA Treatment Study at ESCMID Global 2026
Acurx presents promising data showing DNA pol IIIC inhibitors effectively treat MRSA infections while preserving gut microbiome, addressing key antibiotic concern.
EMA Establishes Expert Panel to Strengthen COVID-19 mRNA Vaccine Trust Including Spikevax and Comirnaty
European Medicines Agency forms international expert panel to enhance public confidence in COVID-19 mRNA vaccines including Spikevax and Comirnaty.
Mundipharma's REZZAYO (Rezafungin) Meets Primary Endpoint in Phase III ReSPECT Trial for Fungal Disease Prevention
Mundipharma announces positive Phase III ReSPECT trial results for REZZAYO (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients.
Sanofi's Nuvaxovid COVID-19 Vaccine Shows Superior Tolerability Over mNEXSPIKE in Phase 4 Study
Sanofi's protein-based Nuvaxovid COVID-19 vaccine demonstrated better tolerability than mNEXSPIKE in first head-to-head phase 4 study presented at ESCMID.
Traws Pharma Advances Tivoxavir Marboxil to Human Influenza Challenge Trial, Reports Positive Ratutrelvir COVID Data
Traws Pharma advances tivoxavir marboxil for once-monthly flu prevention and reports differentiated COVID treatment data for ratutrelvir versus Paxlovid.
Bavarian Nordic's VIMKUNYA Chikungunya Vaccine Receives First Swiss Approval from Swissmedic
Bavarian Nordic receives Swissmedic approval for VIMKUNYA, the first chikungunya vaccine approved in Switzerland for individuals 12 years and older.